Khan Zahid Hussain, Soltani Alireza Ebrahim, Rahmani Payman
Deptartment of Anesthesiology, Imam Khomeini Medical Center, Tehran University of Medical Sciences, Keshavarz Blvd., Tehran 14197, Iran.
J Anesth. 2007;21(2):258-60. doi: 10.1007/s00540-006-0481-y. Epub 2007 May 30.
We report the successful use of recombinant activated factor VII (rFVIIa) infusion in an 18-year-old man who underwent L3 laminectomy and pedicular screw fixation with severe refractory bleeding secondary to severe coagulopathy, which had remained unresponsive to conventional medical and surgical therapies. However, the patient developed a thromboembolic complication presumably associated with the use of rFVIIa. Although rFVIIa provides a dramatic response in intractable bleeding, it may cause a thromboembolic phenomenon which should be vigilantly considered and promptly treated.
我们报告了重组活化凝血因子 VII（rFVIIa）成功用于一名 18 岁男性的案例。该患者接受了 L3 椎板切除术和椎弓根螺钉固定术，因严重凝血障碍导致严重难治性出血，对传统药物和手术治疗均无反应。然而，患者出现了可能与使用 rFVIIa 相关的血栓栓塞并发症。尽管 rFVIIa 在难治性出血中能产生显著效果，但它可能会引起血栓栓塞现象，对此应予以警惕并及时治疗。
